Search | TVST | ARVO Journals

Showing 1 – 15 of 15

SORT: Best Match Most Recent Oldest

VIEW: Basic | Expanded

ARVO Annual Meeting Abstract June 2022

Phase I/IIa study examining the safety and tolerability of single and multiple rising intravitreal doses of BI 836880 in patients with wAMD

Oliver Zeitz; Albert Edwards; Allen Hu; Brian Berger; Gudrun Simons; michael ehrlich; Daniel Peter; Sobha Sivaprasad

Invest. Ophthalmol. Vis. Sci.. 2022; 63(7):3124.

Clinical Trials December 2021

Phase 1 Dose-Escalation Study of Plasma Kallikrein Inhibitor THR-149 for the Treatment of Diabetic Macular Edema

PDF

Pravin U. Dugel; Arshad M. Khanani; Brian B. Berger; Sunil Patel; Mitchell Fineman; Glenn J. Jaffe; Petra Kozma-Wiebe; Jeffrey Heier
TAGS: diabetic macular edema, injections, plasma kallikrein, safety, inflammation, surrogate endpoints, eye
Trans. Vis. Sci. Tech.. 2021; 10(14):28. https://doi.org/10.1167/tvst.10.14.28

Includes: Supplemental Content

Clinical Trials December 2021

Safety and Tolerability of Intravitreal Carotuximab (DE-122) in Patients With Persistent Exudative Age-Related Macular Degeneration: A Phase I Study

PDF

Victor H. Gonzalez; Brian Berger; Roger Goldberg; Carmelina M. Gordon; Rahul N. Khurana; Raymund Angeles; Naveed Shams
TAGS: anti-vascular endothelial growth factor therapy, exudative age-related macular degeneration, persistence, phase 1 clinical trials, safety, intravitreal injections, cohort studies, endoglin, eye
Trans. Vis. Sci. Tech.. 2021; 10(14):27. https://doi.org/10.1167/tvst.10.14.27

Includes: Supplemental Content

Clinical and Epidemiologic Research May 2018

A CCR2/5 Inhibitor, PF-04634817, Is Inferior to Monthly Ranibizumab in the Treatment of Diabetic Macular Edema

PDF

Jeremy D. Gale; Brian Berger; Steven Gilbert; Serghei Popa; Marla B. Sultan; Ronald A. Schachar; Douglas Girgenti; Christelle Perros-Huguet
TAGS: diabetic macular edema, ranibizumab, safety
Invest. Ophthalmol. Vis. Sci.. 2018; 59(6):2659-2669. https://doi.org/10.1167/iovs.17-22731

Includes: Supplemental Content

ARVO Annual Meeting Abstract September 2016

Effect of selective oral inhibition of CCR2/5 chemokine receptors compared to intravitreal ranibizumab on diabetic macular edema (DME)

Brian B Berger; Jeremy Gale; Steven Gilbert; Sergei Popa; Marla Sultan; Ronald Schachar; Rob Webster; Christelle Perros-Huguet

Invest. Ophthalmol. Vis. Sci.. 2016; 57(12):2109.

ARVO Annual Meeting Abstract June 2015

Efficacy of RTH258 (ESBA1008), an Anti-VEGF Agent, Applied by Microvolume Injection or Infusion in Subjects with Neovascular AMD

Brian B Berger; Susan E Yanni; Andreas Wenzel; Andreas Weichselberger; Jean Pierre Hubschman

Invest. Ophthalmol. Vis. Sci.. 2015; 56(7 ):821.

ARVO Annual Meeting Abstract April 2014

Demographics and Baseline Characteristics of the iDEAL Study: A Randomized, Multi-center, Phase II Study of the safety, Tolerability, and Bioactivity of Repeated Intravitreal Injections of iCO-007 as Monotherapy or in Combination with Ranibizumab or Laser Photocoagulation in the Treatment of Diabetic Macular Edema with Involvement of the FoveAL Center

Yasir Sepah; Diana V Do; David Callanan; Victor H Gonzalez; Lawrence Halperin; Brian B Berger; Mostafa Saad Hanout; Peter Hnik; Quan Dong Nguyen

Invest. Ophthalmol. Vis. Sci.. 2014; 55(13):1758.

ARVO Annual Meeting Abstract April 2014

The Course of Eyes with Vitrectomy Prior to Enrollment in a Randomized Trial Evaluating Ranibizumab Plus Prompt or Deferred Laser for Diabetic Macular Edema

Brian B Berger; Diabetic Retinopathy Clinical Research Network

Invest. Ophthalmol. Vis. Sci.. 2014; 55(13):1771.

ARVO Annual Meeting Abstract June 2013

Phase I, Masked, Placebo-Controlled, Single and Multiple Ascending Intravenous Dose Studies Evaluating Systemic and Ocular Safety, Tolerability, and Visual Acuity Effects of RN6G (PF-04382923) in Subjects with Dry, Age-Related Macular Degeneration (ARMD)

Brian Berger; Pamela Garzone; Ivana Gunderson; Philip Fanning; Gilbert Wong; Kai Liao; Steven Hua; John Lin

Invest. Ophthalmol. Vis. Sci.. 2013; 54(15):4505.

Clinical and Epidemiologic Research December 2012

Retinal Thickness in People with Diabetes and Minimal or No Diabetic Retinopathy: Heidelberg Spectralis Optical Coherence Tomography

PDF

Kakarla V. Chalam; Susan B. Bressler; Allison R. Edwards; Brian B. Berger; Neil M. Bressler; Adam R. Glassman; Sandeep Grover; Shailesh K. Gupta; Jared S. Nielsen; for the Diabetic Retinopathy Clinical Research Network
TAGS: diabetes mellitus, diabetes mellitus, type 2, diabetic retinopathy, optical coherence tomography, retinal diseases, eye, cohort studies, volume
Invest. Ophthalmol. Vis. Sci.. 2012; 53(13):8154-8161. https://doi.org/10.1167/iovs.12-10290

ARVO Annual Meeting Abstract March 2012

Multicenter Phase 1 Clinical Trial Targeting Tissue Factor for the Treatment of Neovascular AMD

John A. Wells, III; Brian B. Berger; Christine Gonzales; Victor H. Gonzales; David L. Johnson; Brian D. Sippy; Manju Soni

Invest. Ophthalmol. Vis. Sci.. 2012; 53(14):450.

ARVO Annual Meeting Abstract March 2012

Retinal Thickness in People with Diabetes and Minimal or No Diabetic Retinopathy as Measured by Heidelberg Spectralis Optical Coherence Tomography

Brian B. Berger; Diabetic Retinopathy Clinical Research Network

Invest. Ophthalmol. Vis. Sci.. 2012; 53(14):2872.

ARVO Annual Meeting Abstract March 2012

A Phase I/II Study of Oral Pazopanib, a Receptor Tyrosine Kinase Inhibitor, in Neovascular Age Related Macular Degeneration

Jason S. Slakter; Michael J. Tolentino; Brian B. Berger; Joel Pearlman; Robert Noble; Li Ye; Chun-Fang Xu; Ronald P. Danis; Megan McLaughlin; Robert Kim

Invest. Ophthalmol. Vis. Sci.. 2012; 53(14):2038.

ARVO Annual Meeting Abstract April 2011

Single Ascending Doses of DARPin®, MP0112, Show Potential for Quarterly Dosing in DME

Manjula Patel; Brian B. Berger; Jeffrey S. Heier; David M. Brown; Peter A. Campochiaro; Michael T. Stumpp

Invest. Ophthalmol. Vis. Sci.. 2011; 52(14):582.

ARVO Annual Meeting Abstract April 2011

Expanded Two-year Follow Up Of A Randomized Trial Evaluating Ranibizumab Plus Prompt Or Deferred Laser Or Triamcinolone Plus Prompt Laser For Diabetic Macular Edema

Brian B. Berger; Diabetic Retinopathy Clinical Research Network

Invest. Ophthalmol. Vis. Sci.. 2011; 52(14):5335.

NARROW

Content Type

Journal

Article Type

Topics

Tags

Specify Date Range

Phase I/IIa study examining the safety and tolerability of single and multiple rising intravitreal doses of BI 836880 in patients with wAMD

Phase 1 Dose-Escalation Study of Plasma Kallikrein Inhibitor THR-149 for the Treatment of Diabetic Macular Edema

Safety and Tolerability of Intravitreal Carotuximab (DE-122) in Patients With Persistent Exudative Age-Related Macular Degeneration: A Phase I Study

A CCR2/5 Inhibitor, PF-04634817, Is Inferior to Monthly Ranibizumab in the Treatment of Diabetic Macular Edema

Effect of selective oral inhibition of CCR2/5 chemokine receptors compared to intravitreal ranibizumab on diabetic macular edema (DME)

Efficacy of RTH258 (ESBA1008), an Anti-VEGF Agent, Applied by Microvolume Injection or Infusion in Subjects with Neovascular AMD

The Course of Eyes with Vitrectomy Prior to Enrollment in a Randomized Trial Evaluating Ranibizumab Plus Prompt or Deferred Laser for Diabetic Macular Edema

Phase I, Masked, Placebo-Controlled, Single and Multiple Ascending Intravenous Dose Studies Evaluating Systemic and Ocular Safety, Tolerability, and Visual Acuity Effects of RN6G (PF-04382923) in Subjects with Dry, Age-Related Macular Degeneration (ARMD)

Retinal Thickness in People with Diabetes and Minimal or No Diabetic Retinopathy: Heidelberg Spectralis Optical Coherence Tomography

Multicenter Phase 1 Clinical Trial Targeting Tissue Factor for the Treatment of Neovascular AMD

Retinal Thickness in People with Diabetes and Minimal or No Diabetic Retinopathy as Measured by Heidelberg Spectralis Optical Coherence Tomography

A Phase I/II Study of Oral Pazopanib, a Receptor Tyrosine Kinase Inhibitor, in Neovascular Age Related Macular Degeneration

Single Ascending Doses of DARPin®, MP0112, Show Potential for Quarterly Dosing in DME

Expanded Two-year Follow Up Of A Randomized Trial Evaluating Ranibizumab Plus Prompt Or Deferred Laser Or Triamcinolone Plus Prompt Laser For Diabetic Macular Edema

To View More...

You must be signed into an individual account to use this feature.